# Observational Study to Evaluate the Efficacy and Safety of Bortezomib, Melphalan, Prednisone (VMP) in Participants With Multiple Myeloma

> **NCT02474563** · — · COMPLETED · sponsor: **Janssen Korea, Ltd., Korea** · enrollment: 171 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Bortezomib
- **DRUG:** Melphalan
- **DRUG:** Prednisone

## Key facts

- **NCT ID:** NCT02474563
- **Lead sponsor:** Janssen Korea, Ltd., Korea
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2011-05
- **Primary completion:** 2014-05
- **Final completion:** 2014-05
- **Target enrollment:** 171 (ACTUAL)
- **Last updated:** 2015-06-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02474563

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02474563, "Observational Study to Evaluate the Efficacy and Safety of Bortezomib, Melphalan, Prednisone (VMP) in Participants With Multiple Myeloma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02474563. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*